1. HIV can cause a variety of hematological manifestations including anemia, leukopenia, thrombocytopenia, and coagulation disorders due to bone marrow infiltration and effects on hematopoietic progenitor cells.
2. The bone marrow in HIV/AIDS commonly shows hypercellularity, dysplasia of the erythroid and myeloid lineages, plasmacytosis, and lymphoid aggregates. Opportunistic infections also frequently involve the bone marrow.
3. HIV is associated with increased risk of aggressive B-cell lymphomas such as diffuse large B-cell lymphoma. Lymphomas in HIV often involve extranodal sites and the bone marrow.
Haematological manifestations of HIV by Dr Senani Williams (FRCPath, MD), Consultant Haematologist, Faculty of Medicine, University of Kelaniya, Sri Lanka
Haematological manifestations of HIV by Dr Senani Williams (FRCPath, MD), Consultant Haematologist, Faculty of Medicine, University of Kelaniya, Sri Lanka
This presentation is about anemia of chronic disease, nowadays also called as anemia of Inflammation. I have dealt with anemia in CKD and malignancy in detail.
UAEU - CMHS - Hematology-Oncology Course - MMH 302 - HONC 320. Education material for medical students - It cover basic principles of hematology and oncology, including CAR-T and gene editing. It can be used for study and review. It illustrates main principles of hematology and oncology.
This presentation is about anemia of chronic disease, nowadays also called as anemia of Inflammation. I have dealt with anemia in CKD and malignancy in detail.
UAEU - CMHS - Hematology-Oncology Course - MMH 302 - HONC 320. Education material for medical students - It cover basic principles of hematology and oncology, including CAR-T and gene editing. It can be used for study and review. It illustrates main principles of hematology and oncology.
MPNs; Definition, Types of MPN Mutations, Aetiology, Clinical features, CMLNawsherwan Mohammad
Polycythemia, essential thrombocythemia, and myelofibrosis are three distinct myeloproliferative neoplasms (MPNs) that affect the bone marrow's production of blood cells. Here's a brief overview of each condition:
1. **Polycythemia (Polycythemia Vera):**
- Polycythemia vera (PV) is a disorder where the bone marrow produces too many red blood cells, white blood cells, and platelets. This leads to an increased thickness of the blood (hyperviscosity), which can cause complications like blood clots, strokes, and heart attacks.
- Symptoms may include fatigue, weakness, headaches, dizziness, itching (especially after a warm bath), and redness or a bluish tint to the skin.
- Treatment aims to reduce the risk of blood clots and manage symptoms. It may include phlebotomy (removing blood to lower red cell count), medications to suppress bone marrow activity, and aspirin to reduce clotting.
2. **Essential Thrombocythemia (ET):**
- Essential thrombocythemia is characterized by the overproduction of platelets in the bone marrow. This condition can lead to abnormal blood clotting or bleeding.
- Symptoms may include headaches, dizziness, tingling or numbness in the hands or feet, vision changes, and easy bruising or bleeding.
- Treatment focuses on reducing the risk of blood clots and managing symptoms. This may involve medications to lower platelet counts, such as hydroxyurea or anagrelide, as well as aspirin therapy.
3. **Myelofibrosis:**
- Myelofibrosis is a condition where the bone marrow is replaced by fibrous tissue, leading to a decrease in the production of normal blood cells. It is often associated with anemia, enlarged spleen, and abnormal blood cell counts.
- Symptoms may include fatigue, weakness, abdominal discomfort due to an enlarged spleen, easy bruising or bleeding, and frequent infections.
- Treatment aims to manage symptoms and improve quality of life. This may involve medications to reduce spleen size and control symptoms, blood transfusions for anemia, and, in some cases, stem cell transplant for eligible patients.
These conditions are chronic and require ongoing monitoring and management by healthcare professionals, often including hematologists or oncologists. Treatment plans are tailored to each individual based on factors such as age, overall health, disease progression, and risk of complications.
complete information about the cancer condition that is leukemia - introduction, definition, etiology and causes, pathophysiology ,types, clinical manifestations, diagnosis, nursing management, medical management, nursing research .
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
Anti ulcer drugs and their Advance pharmacology ||
Anti-ulcer drugs are medications used to prevent and treat ulcers in the stomach and upper part of the small intestine (duodenal ulcers). These ulcers are often caused by an imbalance between stomach acid and the mucosal lining, which protects the stomach lining.
||Scope: Overview of various classes of anti-ulcer drugs, their mechanisms of action, indications, side effects, and clinical considerations.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stockrebeccabio
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Telegram: bmksupplier
signal: +85264872720
threema: TUD4A6YC
You can contact me on Telegram or Threema
Communicate promptly and reply
Free of customs clearance, Double Clearance 100% pass delivery to USA, Canada, Spain, Germany, Netherland, Poland, Italy, Sweden, UK, Czech Republic, Australia, Mexico, Russia, Ukraine, Kazakhstan.Door to door service
Hot Selling Organic intermediates
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
2. • A 48-year-old woman
• Presentation
– severe epistaxis.
– hematologic profile
• marked thrombocytopenia (3 x 109/L)
• hemoglobin 11.6 g/dL,
• leukocyte count 5.2 x 109/L
• unremarkable blood film except for rare platelets.
– tested positive for HIV
• CD4 count was low (20/mm3).
– tentative diagnosis HIV–immune thrombocytopenic
purpura (ITP)
– treated with
• antiretroviral medications,
• IVIG,
3. – No improvement.
– After 6 weeks bone marrow examination done.
• The aspirate was dry.
– core biopsy
• hypercellular marrow with heavy infiltrate of
Mycobacterium avium intracellulare infection
– started on 4-drug antituberculosis treatment,
– 2 weeks later her platelet count was 30 x 109/L.
– platelet count steadily rose to 150 x 109/L by
day 20 and was maintained thereafter
4. CASE 2 AFMC NOV 2008
26 yr old lady presented with Fever , Low
backache and significant weight loss with
past history of cervical Lymphadenitis &
exposure to ATT( 2006) .
Spleen palpable 03cm below LCM ,firm, non tender
• Hb - 10.3gm/dl
• TLC - 7600 / cumm
• DLC - P 68L24 M03 E 05
• Platelets - 2.3 x 106
/ μL
• PBS - Microcytic hypochromic picture
• ESR (wg) - 18mm fall in 1st
hr
5. • Spinal Abnormality, kyphosis and gibbus
abnormalities present
• Put on ATT again at Kolhapur
• Presented to us in Nov 2008 with severe
pancytopenia requiring multiple
transfusions
• BM asp BM biopsy suggestive of anaemia
of critically ill and showed florid gelatinous
degeneration
• Thus tested for HIV and found to be
positive
6.
7. What is AIDS
• an HIV infection
• any of the disorders in clinical category B or C of
HIV infection.
– Serious opportunistic infections
– cancers, such as Kaposi's sarcoma and non-Hodgkin
lymphoma, to which defective cell-mediated immunity
predisposes
– Neurologic dysfunction
• or a CD4+ T lymphocyte count of < 200/μL.
CDC disease staging system (most recently revised in 1993)
10. Anaemia
• Most common.
• Throughout the course of illness.
• ART can cause improvement in Hb levels.
• Increased risk of disease progression.
• Shorter survival.
• Decreased quality of life.
11. Etiopathogenesis
• HIV induced effect on bone marrow.
– Ineffective erythropoesis.
– Infection of progenitor cells.
– Negative effect on EPO.
• Nutritional deficiency.
– Fe, B12, Folate.
• Infiltration of BM- infections or tumors.
• Medications.
12. Etiopathogenesis (contd)
• Hemolytic anaemia.
– Intrinsic red cell defect
– Extrinsic red cell defect DCT positive
• Both warm and cold AIHA.
• Increased risk of thromboembolism.
• Thrombocytopenia and fragmented cells in PBS.
• Bleeding.
– GI bleeding due to CMV, NHLs and kaposi.
13. Lab investigations
• PBS-
– Macrocytosis due to AZT.
– Normocytic due to HIV infection.
– Schistocytes .
• Fe indices-
– Low serum Fe and transferrin and high serum
ferritin.
– BM Fe increased
14. Lab investigations (contd)
• Positive DAT-
– 20-43% of hospitalised patients of AIDS.
– Cold agglutinins in 22%.
• B12 levels low.
• Folate levels are normal.
• EPO levels are-
– Low due to post-translational events.
– High in patients with zidovudine associated
anaemia.
15. Leukopenia
• Lymphopenia and neutropenia commonly.
• Impaired granulopoesis.
• Neutropenia due to drugs-
– Pentamidine, gancyclovir, zidovudine.
• Autoimmune distruction.
• PBS –
– hypopigmentation, shift to left, pseudo-pelger huet and
other dysplastic changes.
• Neutrophil function abnormalities.
16. Thrombocytopenia
• <100,000/mm3.
• 3-8% of HIV positive and 30-45% of AIDS.
• Neither a prognostic indicator nor a sign for
progression.
• Any stage of disease.
• Rarely significant bleeding problem.
• Responds to ART.
17. Etiopathogenesis
• Platelet destruction in early course.
• Reduced production in later course.
• Causes-
– Chronic ITP-megakaryocytic .
• Elevated platelet associated antibodies. GpIIIa
• Cross reactivity between anti-HIV and platelet antigens.
– Impaired thrombopoesis-
• Depressed marrow platelet production.
• Low MPV and dyspoetic
– Drug induced
18. TTP
• Pentad of fever, neurological deficit,
thrombocytopenia, oliguria and
microangiopathy.
• PBS-schistocytes, reticulocytosis.
• Indirect hyperbilirubinaemia, raised LDH.
• Precipitated by-infection, drugs, pregnancy
etc.
• More in era before HAART.
19. Etiopathogenesis
• Absence of vWF cleaving protease activity.
• In HIV the cause is IgG autoantibody against
the enzyme.
• Common coexistence of AIDS defining
illnesses.
• CD4+<250/mm3.
• TTP should always be in the list.
20. Coagulation Disorders
• HIV is a prothrombotic condition.
• Low CD4+ count and protease inhibitors
are the culprits.
• Coexistent-APLA, LA, Protein C and S
deficiency, malignancies, autoimmune
disorders.
• Endothelial damage due to tumor cells.
21. Other coagulation protein
abnormalities
• Heparin cofactor II deficiency.
• AT deficiency is reported in HIV patients-
– Malnutrition
– Protein loosing nephropathy.
• Prevalance
– LA=53-70%
– anti-cardiolipin antibodies=46-90%.
• Infections like Hep C, syphilis, PCP cause
production of antibodies.
22. Role of protease inhibitors
• Abnormalities of glucose metabolism and
serum lipids.
• Disturbances of fibrinolysis.
24. Bone Marrow
• Cytological features
– M/E ratio 2-5:1
– Hypercellular,
– normocellular or hypocellular
– Erythroid dysplasia
– Erythroid hypoplasia
• MAC infection,
27. Bone Marrow
• Increased eosinophils
• Iron adequate to increased (reticulo-
endothelial cell distribution)
• Marrow Increased reticulin
• Matrix Necrosis
• Serous atrophy
28. Etiopathogenesis
• Infection of MSCs with HIV-
– Abrogates growth
– Hematopoetic supportive function.
• Defective progenitor growth-
– Secondary to suppressor T-cell.
– Inversely proportional to T4 to T8 ratio.
• CD34 progenitor cell – infected with HIV.
29. Etiopathogenesis
• HIV infection of Monocyte/Macrophage-
– Exaggerated TNF, IL-1 and TGF-b
– Development of immunodeficiency.
– HIV-1 dementia.
• HIV infection of microvascular endothelial
cells-
– Poor response to IL-1a.
– Impaired release of IL-6 and G-CSF
30. Dyserythropoesis
• Most common, includes-
– Changes in erythroblasts –
• Lobulations
• Binucleation and fragmentation-
• Basophilic stippling in later stages.
• Florid megaloblastic changes
• Unrelated to B12, folate and drugs.
– Erythroid hypoplasia-
• In AIDS, ARC, Ziduvudine and MAC infection.
• PRCA secondary to parvovirus B19.
32. Dysmegakaryopoesis
• Can be with or without thrombocytopenia.
• Dysplastic changes-
– Micromegs with denuded nuclei
– Hyposegmented megs
– Fragmented nuclei
– Clustering of megs.
• Dysplastic changes and presence of HIV RNA
in megs
33.
34. Cellularity
• BM is difficult to aspirate.
– Focal or diffuse increase in reticulin
• Normo to hypercellular.
– Myeloid dysplasia
– Ineffective erythropoesis
• M:E ratio of 2-7:1
– Myeloid hyperplasis
– Erythroid hypoplasia.
35. Plasma cell abnormalities
• Increase seen in 31-85% people.
• Due to-
– Physiological response to antigenic stimulation.
– Dysregulated B-cell proliferation.
– Seen in all stages.
• Morphology
– Dysplasia, large bi or tri nucleate
– In clusters
36. Plasma cell abnormalities
• Russel bodies, multiple globules.
• Myeloma is clearly reported in AIDS.
• Monoclonal spikes on serum electrophoresis.
• Marrow plasmacytosis
• Atypical forms.
• Without demonstration of clonality.
• Paraproteinemia
activity against HIV gag & pol
Vigrous immune response to HIV.
37. Lymphoid aggregates
• 10-50% of patients of AIDS-ARC.
• Small, round, well circumscribed- small
lymphocytes.
• Large poorly defined mixed with histiocytes.
• Atypical, cleaved lymphocytes-paratrabecular
40. Why HIV- Associated
• Sharp decline post HAART
• Similar geographic distribution
• Same risk group individuals
• Not responding to chemo as other lymphomas
• More extranodal spread , BM commonest
41. HIV –associated lymphomas
• Co-infection with HIV and KSHV/HHV-8
• Liquid phase
• No masses or adenopathy
• Fever, night sweats, weight loss and
hepatosplenomegaly.
43. Plasmablastic lymphoma
• Cells resemble B-immunoblasts
• Immunphenotypically plasma cells
• Highest incidence in HIV-patients
• Mass in oral cavity, extranodal sites
• Diffuse and cohesive proliferation
• EBV associated
• CD 38,138 positive-CD 45,20 negative.
44.
45. PCNSL
• CD4< 50.
• Also large cell lymphomas
• EBV associated
• Lack c-myc translocation
• Responds well to HAART.
46. HIV associated HD
• HD not a part of CDC definition
• More aggressive, extranodal, BM involvment
• Less mediastinal adenopathy
• Mixed cellularity or LDHL
• CD4< 300/dl
49. Miscellaneous
• Increased histiocytes-
– Showing hemophagocytosis.
– Non-caseating granulomas.
– Loose granulomas.
– Triggered by HIV itself.
• Increased number of
histiocytes→hemophagocytic
syndrome→severe pancytopenia.
50.
51. Miscellaneous
• Pseudogaucher cells-MAC infection.
• Marrow eosinophilia is common: 9-61% of
AIDS patient.
• BM iron stores↑.
• Sideroblasts have been described.
• Granulomas are also infrequent.
52.
53. BM matrix
• Increased reticulin or fibrosis.
– Focal
– diffuse
• “Gelatinous Transformation”.
• Make aspiration difficult.
57. Oppurtunistic infections
• Histology or culture is useful.
• Undiagnosed fever or constitutional
symptoms.
• Low CD4+ count.
• BM cultures as sensitive as blood.
• BM better due special histological staining.
58.
59.
60. HAART and BM changes
• HAART and immune reconstitution –
increased whole blood count.
• Increase in LTC-IC.
• HAART-
– Controlled HIV replication.
– Restored stem cell activity.
Editor's Notes
A 48-year-old woman presented with severe epistaxis. Her hematologic profile showed marked thrombocytopenia (3 x 109/L), hemoglobin 11.6 g/dL, leukocyte count 5.2 x 109/L, and an unremarkable blood film except for rare platelets. She tested positive for HIV and the CD4 count was low (20/mm3). A tentative diagnosis of HIV–immune thrombocytopenic purpura (ITP) was made. She was treated with antiretroviral medications, IVIG, and subsequently with steroids for 4 weeks without improvement. Rituximab was deemed unsafe because of her immunosuppressed status. After 6 weeks of platelet unresponsiveness, a bone marrow examination was performed. The aspirate was dry. The core biopsy showed a hypercellular marrow with a heavy infiltrate of Mycobacterium avium intracellulare infection (ZN stain in figure). She was started on 4-drug antituberculosis treatment, and 2 weeks later her platelet count was 30 x 109/L. The platelet count steadily rose to 150 x 109/L by day 20 and was maintained thereafter
So the first lesson learnt is there is more to HIV than eye can see.
Retroviruses are enveloped RNA viruses defined by their mechanism of replication via reverse transcription to produce DNA copies that integrate in the host cell genome.
CDC A#, B3, C1, C2 and C3 are AIDs classifies AIDS as an HIV infection with CD4 cell count of less than 200 and those with certain HIV related conditions and symptoms. WHO classification is used in resource strained settings and defines AIDS categories on the basis of clinical manifestations. CDC (Central of disease control) CD4 normal 400-1500.
Philia- affinity
BM supression through abnormal cytokine production and alteration in BM microenvironment. Can be both reduced intake or absorption. Infections like MAC, PCP, histoplasma, parvovirus. Kaposi sarcoma and NHLs. Zidovudine, septran, ganciclovir, amphotericin B.
Mechanisms proposed for AIHA include antierythrocyte antibodies, non-specific coating of red cells by Ig, presence of immune complexes and abnormal B cell regulation.
Direct hiv effect, oppurtunistic inf and neoplasia megalocytes, increased granulation and peroxidase activity phacocytic and intracellular killing of microbes is affected
HIV INFECTION SHOULD BE SUSPECTED IN PATIENTS PRESENTING WITH UNEXPLAINED THROMBOCYTOPENIA.
Megakaryocytes bear CD4 receptor. Platelet destruction due to antibodies, infections, sple3nomegaly and fever. Production reduces due to reduced CD34 and megakaryoctic diffrentiation.
In patients with asymptomatic HIV infection response to therapy is similar to that seen in HIV negative persons, however in those with advanced HIV disease outcome is often dismal.
Inability to cleave high molecular wt vWF synthesized by endothelial cells. Like pcp, kaposi, cryptococcus and CMV. Of treating physicians as plasmapheresis provides substantial symptomatic relief .
Ad fuel to the fire.
Is more prevalent in hiv. It is a specific thrombin inhibitor whose inhibitory activity is enhanced by heparin and deficiency causes recurrent thrombosis.
One should be alert about the possibility of unprovoked thrombosis in patients of HIV infection and possibility of increased lipid levels in patients on protease inhibitors.
Hiv infection of stromal cells produces inhibitory factors which suppresses clonogenic potential of MSC. There is now ample evidence that CD34 progenitor cells can be infected by HIV
However these may accentuate it.
Dyserythropoiesis with megaloblastic changes and nuclear bridging in MDS associated with previous high BZ exposure. Bone marrow aspirate with Wright–Giemsa stain (original magnification 1000×). Reproduced with permission [11].
Ultrastructural changes are marked balloning and blebbing of peripheral zone…….as seen in myeloproliferative neoplasms……..along with clinical response to patients with Zidovudine are all consistent with the view meg itself is the target for Hiv infection.
True marrow cellularity is appreciated on trephine biopsy…….even in the setting of peripheral cytopenias in a majority of patients…therefore hypercellularity of the marrow in the face on cytopenias is common in HIV
By viruses and other antigenic stimulation or may be secondary to.
In paratrabecular localization it is important to r/o NHL, since lymphoma in AIDS patients is commoner than benign lymphoid aggregates.
AIDS was first described in 1981 and in 1985 CDC included HIV patients with aggressive B-cell NHL, also as AIDS. Currently The list is not exhaustive and includes
PEL and PMCD…..spreading along serous membranes.
Aggressive B-cell lymphomas include………DLBCL is centroblastic /immunoblastic…….Burkitt is classical/BL with plasmacytoid diffrentiation and atypical BL
Like mucosal membranes, including sinonasal cavity, bone marrow and skin. Plasmablastic lymphomas not associated with HIV are common in lymphnodes. High proliferation index Ki-67 &gt;90%
Plasmablastic Lymphoma: This aggressive variant of diffuse large B-cell lymphoma usually occurs in the oral cavity of HIV positive patients, monomorphic population of large immunoblastic population with prominent nucleoli….. Starry sky pattern.
Becoz of no clear demonstration of its increased incidence in conjunction.
Hodgkin lymphoma infiltration of the bone marrow. A Reed-Sternberg cell is highlighted by the black arrow. Malignant bone marrow infiltrations often present with cytopenias.
HIV-infected persons have an elevated risk of developing non-Hodgkin&apos;s lymphoma (NHL); this risk remains increased in the era of effective HIV therapy. We evaluated serum immunoglobulin (Ig) proteins as predictors of NHL risk among HIV-infected individuals. DUE TO DYSREGULATED B-CELL FUNCTION
Aggregates of histiocytes, plasma cells and lymphocytes……...no obvious second infection, HIV itself triggered histiocyte proliferation and phagocytosis.
Hematophagocytosis accompanying MDS-Eo associated with previous high BZ exposure. Activated histiocytic cells exhibit prominent phagocytosis of degenerating erythroid granulocytic cells typical of an immune-mediated inflammatory process. Bone marrow aspirate with Wright–Giemsa stain (original magnification 1000×). Reproduced with permission [11].
In …which foamy histiocytes were described on Giemsa stain….. Although peripheral blood eosiniphiliais rarely seen….…indicating a defect in Fe utilization…….but are uncommon.
Also called serous atrophy.
Bone marrow biopsies from post-transplant, immunocompromised patients are evaluated for the presence of primary marrow defects (eg. drug induced cytopenias), infiltrative processes (eg. metastatic carcinoma and epstein-barr virus-related post-transplant lymphoproliferative disorder), and opportunistic infections (eg. fungal, viral, mycobacterial). Although the bone marrow biopsy from this patient is insufficient to assess hematopoiesis, numerous loose collections of foamy macrophages were identified. Special stains for acid fast bacilli [inset] revealed the presence of abundant mycobacteria. Given the clinical history and the number of mycobacteria seen, this finding supports the diagnosis of infection with mycobacterium avium complex (MAC).
cryptococcus
Long term culture initiating cells…………in experiments .Probably by supressing cytokines which inhibit normal hematopoesis